Clinical research
Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that its ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).
The combination of Opdivo and Yervoy actually fared worse than placebo, according to the data presented at the conference.
Gyroscope Therapeutics, headquartered in Stevenage, UK, is merging with Ambler, Pennsylvania-based Orbit Biomedical. They will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.
New data shows that patients are extremely satisfied with the medication. Data also showed that through 48 weeks, 84 percent of patients achieved undetectable viral loads, while 8 percent had virologic failures
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
Pharma and biotech companies from Asia to Europe provide updates on business and clinical activities.
Since taking over the role of chief executive officer at Bothell, Wash.-based Alder BioPharmaceuticals in June 2018, Robert Azelby has maintained his focus on moving the company closer to launching its first commercial product in the migraine treatment space.
Researchers with the Icahn School of Medicine at Mount Sinai in New York have had promising results with a cancer vaccine in an early-stage clinical trial. They published their work in the journal Nature Medicine.
TLC announced the earlier-than-scheduled full enrollment in Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy.
PRESS RELEASES